rIL-2 in metastatic soft tissue sarcomas refractory to chemotherapy: Response and enhancement of further chemosensitivity

Anticancer Research

Volumn 18, Issue 5 B, 1998, Pages 3699-3704

  Gravis, G ^a   Viens, P ^a   Delva, R ^b   Baume, D ^d   Blaise, D ^a   Ternier, F ^a   Houvenaeghel, G ^a   Brandely, M ^c   Resbeut, M ^a   Maraninchi, D ^a  

^a INSTITUT PAOLI CALMETTES   (France)

^b CENTRE PAUL PAPIN   (France)

^c SANOFI   (France)

^d Surgery Department Institut Paoli Calmettes ^*

Author keywords

Chemosensitivity; High dose rIL 2; Interleukin 2; rIL 2 in metatastic soft tissue sarcomas; Soft tissue sarcomas

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; DACTINOMYCIN; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; IFOSFAMIDE; RECOMBINANT INTERLEUKIN 2; THIOTEPA; VINCRISTINE; VINDESINE;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; DRUG EFFICACY; DRUG TOXICITY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG METASTASIS; MALE; METASTASIS; PRIORITY JOURNAL; SOFT TISSUE SARCOMA;

EID: 0031700592     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Subramanian S and Wiltshaw E: Chemotherapy of sarcoma - A comparison of three regimens. Lancet 1: 683-686, 1978.
2. Yap B, Sinkovics J and Benjamin R: Survival and relapse patterns of complete responders in adults with advanced soft tissue sarcomas. Proc Am Assoc Cancer Res 20: 352, 1979.
3. Elias A, Ryan L, Sulkes A et al: Response to mesna, doxorubicin, if osfamide and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy. J Clin Oncol 7: 1208-1216, 1989.
4. Pinedo H, Mouridsen H and Branwell V: Anthracycline analogs in advanced soft sarcomas. Two EORTC randomized phase II studies. In: Management of soft tissue and bone sarcomas (Von Oosterom Aand Van Unnik J, eds), NewYork, Raven Press, 1986, pp 169-185.
5. Borden E, Amato D, Enterline H et al: Randomized comparison of Adriamycin regimens for treatment of metastatic soft tissue sarcomas. Proc Am Soc Clin Onc 2: 231, 1983.
6. Schoenfeld D, Rosenbaum C, Horton J et al: A comparison of adriamycin versus vincristine and adriamycin, and cyclophosphamide versus vincristine, actinomycine-D and cyclophosphamide for advanced sarcoma. Cancer 50: 2757-2762, 1982.
7. O'Bryan R, Baker L, Gottlieb J et al: Dose response evaluation of adriamycin in human neoplasia. Cancer 39: 1940-1948, 1977.
8. Benjamin R, Legha S, Patel S et al: Single-agent ifosfamide studies in sarcomas of soft tissue and bone: the M.D.Anderson experience. Cancer Chemother Pharmacol 31: S174-79, 1993.
9. Antman K, Ryan L, Elias A et al: Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcomas. J Clin Oncol 7: 126-131, 1989.
10. Elias A, Eder J, Shea T et al: High-dose if osfamide with mesna uroprotection: a phase I study. J Clin Oncol 8: 170-178, 1990.
11. Gottlieb J, Benjamin R, Baker L et al: Role of DTIC (NSC-45388) in the chemotherapy of sarcomas. Cancer Treat Rep 60: 199-203, 1976.
12. Buesa J, Mouridsen H, Van Oosterom A et al: High-dose DTIC in advanced soft-tissue sarcomas in the adult: a phase II study of the EORTC STBSG. Ann Oncol 2: 307-309, 1991.
13. Antman K, Crowley J, Balcerzak S et al: An intergroup phase III randomized study of doxorubicin and dacarbazine with or without if osfamide and Mesna in advanced soft tissue and bone sarcomas. J Clin Oncol 11: 1276-1285, 1993.
14. Santoro A, Tursz T, Mouridsen H et al: Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for research and treatment of cancer soft tissue and bone sarcoma group. J Clin Oncol 13: 1537-1545, 1995.
15. Mule J, Shu S, Schwarz S et al: Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science 225: 1487-1489, 1984.
16. Mule J, Shu S and Rosenberg S: The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo. J Immunol 135: 646-652, 1985.
17. Rosenberg S, Lotze M, Muul L et al: Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 313: 1485-1492, 1985.
18. Viens P, Blaise D, Stoppa A et al: Interleukin-2 in association with increasing doses of interferon-gamma in patients with advanced cancer. J Immun 11: 218-224, 1992.
19. World Health Organization (1988): International Histologic classification of tumours. Geneva: World Health Organization, 1969-1981; 2nd ed. Berlin: Springer-Verlag, 1988-Present.
20. Rosenberg S, Lotze M, Muul L et al: A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316: 889-897, 1987.
21. Paciucci P, Holland J, Glidewell et al: Recombinant interleukin-2 by continuous infusion and adoptive transfer of recombinant interleukin-2 activated cells in patients with advanced cancer. J Clin Oncol 7: 869-878, 1989.
22. Kim H, Zhou M, Pais R et al: Effect and kinetics of interleukin-2 (IL-2) in pediatric malignancies. Proc Annu Meet Am Assoc Cancer Res, 31: A 1040, 1990.
23. Nasr S, Mc Kolanis J, Pais R et al: A phase I study of interleukin-2 in children with cancer and evaluation of clinical and immunologie status during therapy. Cancer 64: 783-788, 1989.
24. Salem P, Zukiwski A, Benjamin R et al: Arterial infusion of interleukin-2 (IL-2) for treatment of hepatic metastases from GI leiomyosarcoma: predisposition to hypersensitivity to iodine-containing media. Proc Annu Meet Am Soc Clin Oncol 8: A1252, 1989.
25. Toma S, Melioli G, Palumbo R et al: Recombinant interleukin-2 and alfa-2a-interferon in pre-treated advanced soft tissue sarcomas. Int J Oncol 2: 997-1001, 1993.
26. Toffoli G, Frustaci S, Tumiotto L et al: Expression of MDR 1 and GST-pi in human soft tissue sarcomas: relation to drug resistance and biological aggressiveness. Annal Oncol 3: 63-69, 1992.
27. Fogler W, Pearson J, Volker K et al: Enhancement by recombinant human interferon alfa of the reversal of multidrug resistance by MRK-16 monoclonal antibody. J Natl Cancer Inst 87: 94-104, 1995.
28. Reddy P, Graham G, Datta S et al: Effect of recombinant fibroblast interferon and recombinant immune interferon on growth and the antigenic phenotype of multidrug-resistant human glioblastoma multiform cells. J Natl Cancer Inst 83: 1307-1315, 1991.
29. Gambacorti-Passerini C, Rivoltini L, Supino R, et al: Susceptibility of chemoresistant murine andhuman tumor cells to lysis by interleukin-2 activated lymphocytes. Cancer Res 48: 2372-2376, 1988.
30. Scala S, Pacelli R, Iaffaioli R et al: (1991) Reversal of adriamycin resistance by recombinant alpha-interferon in multidrug-resistant human colon carcinoma LoVo-doxorubicin cells. Cancer Res 51: 4898-4902, 1991.
31. Le Cesne A, Vassa G, Farace F et al: Concomitant r-IL2 / doxorubicin (ADR) schedule in advanced adult solid tumors (AST): a circumvention of ADR resistance in soft tissue sarcomas (STS)? Proc of ASCO 15: 521, 1996.